BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that Dipal Doshi, Chief Executive Officer, will deliver a company presentation at the 44 th Annual J ...

Pink slips have followed the green light at Entrada Therapeutics. Weeks after the FDA lifted a more than two-year-long hold, the biotech has set out plans to reduce its workforce by 20% and prioritize ...

Are you feeling called to be one of them? We invite you to apply for the Entrada Scholars Program: a two-week, on-campus, college-level experience that helps you grow as a leader and thrive as a first ...

Entrada Therapeutics' stock has dropped significantly due to FDA holds on two IND applications, but recent insider buying suggests potential upside. The company's EEV platform aims to target ...

Shares of Entrada Therapeutics Inc. rallied 15% in premarket trading on Thursday after the company announced a deal with Vertex Pharmaceuticals Inc. that aims to develop treatments for myotonic ...

Entrada Therapeutics reported a 3Q25 GAAP EPS loss of –$1.06 and revenue of $1.6 million, reflecting declining collaboration income. TRDA is heavily investing in its Duchenne muscular dystrophy ...

At the beginning of 2016, Peter Kim, PhD, was at the Ventura Beach Marriott Hotel in Southern California for a Gordon Research Conference, not long after he had resigned from his position as president ...

Entrada Therapeutics has debuted with a $59 million series A and a plan to deliver biologic therapies intracellularly to treat rare and fatal monogenic diseases. The Boston-based company will start by ...

BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today reported financial results for the fourth quarter and full year ended December 31, 2024 and highlighted recent ...

BOSTON--(BUSINESS WIRE)--Entrada Therapeutics Inc., a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today ...

La administración de Trump está ampliando su prohibición de entrada para incluir a cinco países más e imponer nuevos límites a otros.